China Approves IM19 CAR T for Later-Line Large B Cell Lymphoma

Previously missed November 5 event, confirmed by a company announcement and the regulator-linked Chinese announcement on November 6: China approved poji-ocel (IM19, Saibohua), an autologous CD19 CAR T therapy, for adults with relapsed or…













